Nice find/reminder. Mazen also worked for Madrigal
Post# of 153903
(Total Views: 451)
Posted On: 10/09/2024 8:45:42 PM
Nice find/reminder. Mazen also worked for Madrigal. As recently as April. Great member for our SBA.
Mazen Noureddin, MD, MHSc
Dr. Noureddin is the current Director of the Houston Liver Institute and former founding Director of the Fatty Liver Program at Cedars-Sinai. He completed his residency at the University of Southern California and completed a hepatology fellowship at the NIH and gastroenterology fellowship at University of California San Diego.
Dr. Noureddin has led efforts in several breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those with advanced fibrosis and cirrhosis. He also focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver transplant, liver cancer, new imaging modalities, and exploring new treatments.
Dr. Noureddin has conducted more than 40 investigational clinical studies of novel treatments for non-alcoholic steatohepatitis (NASH). Dr. Noureddin has published 180 papers in the field of NASH in many journals including: The Lancet, Lancet Gastroenterology & Hepatology, Science Trinational Medicine, Gastroenterology, Journal of Hepatology, Journal of Clinical Investigation, Hepatology, Clinical Gastroenterology and Hepatology and others.
Mazen Noureddin, MD, MHSc
Dr. Noureddin is the current Director of the Houston Liver Institute and former founding Director of the Fatty Liver Program at Cedars-Sinai. He completed his residency at the University of Southern California and completed a hepatology fellowship at the NIH and gastroenterology fellowship at University of California San Diego.
Dr. Noureddin has led efforts in several breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those with advanced fibrosis and cirrhosis. He also focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver transplant, liver cancer, new imaging modalities, and exploring new treatments.
Dr. Noureddin has conducted more than 40 investigational clinical studies of novel treatments for non-alcoholic steatohepatitis (NASH). Dr. Noureddin has published 180 papers in the field of NASH in many journals including: The Lancet, Lancet Gastroenterology & Hepatology, Science Trinational Medicine, Gastroenterology, Journal of Hepatology, Journal of Clinical Investigation, Hepatology, Clinical Gastroenterology and Hepatology and others.
(3)
(0)